Trials / Unknown
UnknownNCT02977364
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be observed in advanced cancer patients. To determine the recommended dosage regimen for phase II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10241 |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2018-11-01
- Completion
- 2021-11-01
- First posted
- 2016-11-30
- Last updated
- 2016-11-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02977364. Inclusion in this directory is not an endorsement.